KalVista Pharmaceuticals (KALV) Capital Expenditures Growth (3y) (2019 - 2025)
KalVista Pharmaceuticals (KALV) Capital Expenditures Growth (3y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -31.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -31.94% |
| Apr 30, 2025 | 26.24% |
| Oct 31, 2024 | -43.27% |
| Jul 31, 2024 | -39.36% |
| Apr 30, 2024 | -112.80% |
| Jan 31, 2024 | 173.37% |
| Oct 31, 2023 | -46.42% |
| Jul 31, 2023 | -35.15% |
| Apr 30, 2023 | 105.08% |
| Oct 31, 2022 | 18.98% |
| Jul 31, 2022 | 110.95% |
| Apr 30, 2022 | -32.12% |
| Jan 31, 2022 | 116.16% |
| Oct 31, 2021 | 17.22% |
| Jul 31, 2021 | -20.21% |
| Apr 30, 2021 | -68.78% |
| Jan 31, 2021 | -57.47% |
| Oct 31, 2020 | -36.59% |
| Jul 31, 2020 | -41.52% |
| Apr 30, 2020 | 4.55% |